0001181431-13-007974.txt : 20130208 0001181431-13-007974.hdr.sgml : 20130208 20130208161306 ACCESSION NUMBER: 0001181431-13-007974 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130206 FILED AS OF DATE: 20130208 DATE AS OF CHANGE: 20130208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doberstein Stephen K CENTRAL INDEX KEY: 0001480111 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 13586928 MAIL ADDRESS: STREET 1: 129 ELSIE STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4 1 rrd369528.xml ANNUAL EQUITY COMPENSATION X0306 4 2013-02-06 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001480111 Doberstein Stephen K 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 0 1 0 0 Chief Scientific Officer Stock Option 8.80 2013-02-06 4 A 0 50000 0 A 2021-02-05 Common Stock 50000 50000 D Stock Option 8.80 2013-02-06 4 A 0 50000 0 A 2021-02-05 Common Stock 50000 50000 D This option was granted on February 6, 2013 and vests in monthly installments over the four-year period following the grant date. This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of four (4) years from the grant date (February 6, 2013). The performance-based vesting condition will be met only if Nektar (or a licensee) files a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program including, without limitation, the following: (1) naloxegol (an oral peripherally-acting opioid antagonist); (2) etirinotecan pegol (a topoisomerase I inhibitor); (3) NKTR-061/Amikacin Inhale (a drug-device combination for an inhaled solution of amikacin); or (4) BAX-855 (a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein). Gil M. Labrucherie, Attorney-in-Fact 2013-02-08